MHRA paediatric investigation plan
LIVE ATTENUATED MEASLES VIRUS (SCHWARZ STRAIN) (LIVE ATTENUATED MEASLES VIRUS (SCHWARZ STRAIN))
MHRA paediatric investigation plan MHRA-101277-PIP01-23 · Waiver
Key facts
| PIP number | MHRA-101277-PIP01-23 |
|---|---|
| Active substances | LIVE ATTENUATED MEASLES VIRUS (SCHWARZ STRAIN), LIVE ATTEN'D MUMPS VIRUS (RIT 4385 DERIVED FROM JERYL LYNN), LIVE ATTENUATED RUBELLA (WISTAR RA 27/3 STRAIN), Varicella virus Oka strain (live, attenuated) |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of measles, mumps, rubella and varicella |
| Decision | W: decision granting a waiver in all age groups for the listed condition(s). |
| Published | Jun 24, 2024 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: